Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry
Alberto Carmona‐Bayonas(Hospital General Universitario Morales Meseguer), Javier Gállego(Hospital General Universitario de Elche), Alfonso Martín Carnicero(Hospital San Pedro), E. Buxó Orra(Hospital de Sant Pau), María Luisa Limón(Sorbonne Université), Juana María Cano(Complejo Hospitalario de Navarra), Laura Visa(Hospital Del Mar), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Aitor Azkárate(Hospital Universitario Insular de Gran Canaria), Federico Longo(Instituto Cajal), Ismael Macías(Hospital de Galdakao), Ana Custodio(Hospital Universitario La Paz), M. Mangas Izquierdo(Hospital de Galdakao), E. Castro(Marqués de Valdecilla University Hospital), A. Lacalle(Hospital General Universitario Gregorio Marañón), A. Ramchandani Vaswani(Hospital Universitario Insular de Gran Canaria), Ana Fernández Montés(Instituto Cajal), I. Echavarria Diaz-Guardamino(Hospital General Universitario Gregorio Marañón), Raquel Hernández(Hospital Municipal de Badalona)
Cited by 0
Related Papers
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
|New England Journal of Medicine|2024|208
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
|Nature Communications|2023|65